Theravance Biopharma, Inc. (TBPH)
17.03
0.00 (0.00%)
USD |
NASDAQ |
Oct 02, 16:00
Theravance Biopharma EPS Diluted (Quarterly) : -0.1142 for June 30, 2026
EPS Diluted (Quarterly) Chart
Historical EPS Diluted (Quarterly) Data
| Date | Value |
|---|---|
| June 30, 2026 | -0.1142 |
| March 31, 2026 | -0.0962 |
| December 31, 2025 | 1.150 |
| September 30, 2025 | 0.0696 |
| June 30, 2025 | 1.081 |
| March 31, 2025 | -0.2732 |
| December 31, 2024 | -0.3149 |
| September 30, 2024 | -0.2589 |
| June 30, 2024 | -0.3391 |
| March 31, 2024 | -0.2416 |
| December 31, 2023 | -0.1722 |
| September 30, 2023 | -0.1709 |
| June 30, 2023 | -0.276 |
| March 31, 2023 | -0.351 |
| December 31, 2022 | -0.1538 |
| September 30, 2022 | -2.972 |
| June 30, 2022 | -0.1074 |
| March 31, 2022 | -0.3448 |
| December 31, 2021 | -0.4331 |
| September 30, 2021 | -0.4799 |
| June 30, 2021 | -0.798 |
| March 31, 2021 | -1.236 |
| December 31, 2020 | -0.917 |
| September 30, 2020 | -1.163 |
| June 30, 2020 | -1.000 |
| Date | Value |
|---|---|
| March 31, 2020 | -1.397 |
| December 31, 2019 | -1.169 |
| September 30, 2019 | -1.046 |
| June 30, 2019 | -0.7174 |
| March 31, 2019 | -1.321 |
| December 31, 2018 | -0.9199 |
| September 30, 2018 | -1.096 |
| June 30, 2018 | -0.7587 |
| March 31, 2018 | -1.222 |
| December 31, 2017 | -1.64 |
| September 30, 2017 | -1.27 |
| June 30, 2017 | -1.268 |
| March 31, 2017 | -1.266 |
| December 31, 2016 | -1.36 |
| September 30, 2016 | -0.73 |
| June 30, 2016 | -1.06 |
| March 31, 2016 | -1.10 |
| December 31, 2015 | -1.23 |
| September 30, 2015 | -1.40 |
| June 30, 2015 | -1.42 |
| March 31, 2015 | -1.29 |
| December 31, 2014 | -2.02 |
| September 30, 2014 | -1.72 |
| June 30, 2014 | -1.83 |
| March 31, 2014 | 0.00 |
EPS Diluted (Quarterly) Range, Past 5 Years
--
Minimum
--
Maximum
--
Average
--
Median
EPS Diluted (Quarterly) Benchmarks
| Viatris, Inc. | -0.1021 |
| Ocular Therapeutix, Inc. | -0.3501 |
| ANI Pharmaceuticals, Inc. | 1.052 |
| Corcept Therapeutics, Inc. | 0.356 |
| Veru, Inc. | -0.3032 |
EPS Diluted (Quarterly) Related Metrics
| Net Income (Quarterly) | -5.898M |
| Revenue (Quarterly) | 20.73M |
| Total Expenses (Quarterly) | 26.63M |
| Enterprise Value | 567.41M |
| Gross Profit Margin (Quarterly) | 93.04% |
| Profit Margin (Quarterly) | -28.45% |
| Earnings Yield | 5.93% |
| Operating Earnings Yield | 0.25% |
| Normalized Earnings Yield | 7.024 |